Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Non-Current Debt (2024 - 2025)

bioAffinity Technologies (BIAF) has disclosed Non-Current Debt for 2 consecutive years, with $41313.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 104.72% to $41313.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41313.0 through Dec 2025, up 104.72% year-over-year, with the annual reading at $41313.0 for FY2025, 104.72% up from the prior year.
  • Non-Current Debt for Q4 2025 was $41313.0 at bioAffinity Technologies, down from $43658.0 in the prior quarter.
  • The five-year high for Non-Current Debt was $48156.0 in Q1 2025, with the low at $20180.0 in Q4 2024.